Home › Research › Treatments
Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
Paula López-García, María M. Tejero-Ojeda, María Eugenia Vaquero, Mariano Carrión‐Vázquez. Progress in Neurobiology, 2025-02-28
Topic: Amyloid, tau and blood-test diagnosis
Amyloid proteins have long been in the spotlight for being involved in many degenerative diseases including Alzheimer´s, Parkinson´s or type 2 diabetes, which currently cannot be prevented and for which there is no effective treatment or cure. Here we provide a comprehensive review of inhibitors that act directly on the amyloidogenic pathway (at the monomer, oligomer or fibril level) of key pathological amyloids, focusing on the most representative amyloid-related diseases. We discuss the latest advances in preclinical and clinical trials, focusing on cutting-edge developments, particularly on nanomaterials-based inhibitors, which offer unprecedented opportunities to address the complexity of protein misfolding disorders and are revolutionizing the landscape of anti-amyloid therapeutics. Notably, nanomaterials are impacting critical areas such as bioavailability, penetrability and functionality of compounds currently used in biomedicine, paving the way for more specific therapeutic solutions tailored to various amyloid-related diseases. Finally, we highlight the window of opportunity opened by comparative analysis with so-called functional amyloids for the development of innovative therapeutic approaches for these devastating diseases.
Key findings
- Amyloid proteins have long been in the spotlight for being involved in many degenerative diseases including Alzheimer´s, Parkinson´s or type 2 diabetes, which currently cannot be prevented and for which there is no effective treatment or cure.
- Here we provide a comprehensive review of inhibitors that act directly on the amyloidogenic pathway (at the monomer, oligomer or fibril level) of key pathological amyloids, focusing on the most representative amyloid-related diseases.
- We discuss the latest advances in preclinical and clinical trials, focusing on cutting-edge developments, particularly on nanomaterials-based inhibitors, which offer unprecedented opportunities to address the complexity of protein misfolding disorders and are revolutionizing the landscape of anti-amyloid therapeutics.
- Notably, nanomaterials are impacting critical areas such as bioavailability, penetrability and functionality of compounds currently used in biomedicine, paving the way for more specific therapeutic solutions tailored to various amyloid-related diseases.
- Finally, we highlight the window of opportunity opened by comparative analysis with so-called functional amyloids for the development of innovative therapeutic approaches for these devastating diseases.
Why it matters
This review covers inhibitors acting directly on the amyloidogenic pathway at the monomer, oligomer or fibril level, and discusses preclinical and clinical advances including nanomaterial-based inhibitors. It notes that amyloid-related diseases including Alzheimer's currently cannot be prevented and have no effective treatment or cure.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Progress in Neurobiology) |
| Journal's citation record | 3 / 4 | Progress in Neurobiology: journal h-index 325 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mariano Carrión‐Vázquez: h-index 30 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Consejo Superior de Investigaciones Científicas: institution h-index 1,048 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40024279) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.pneurobio.2025.102734
- PubMed: 40024279
- Original source →
- Free full text: Progress in Neurobiology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
López-García, P., Tejero-Ojeda, M. M., Vaquero, M. E., & Carrión‐Vázquez, M. (2025). Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2025.102734
Vancouver
López-García P, Tejero-Ojeda MM, Vaquero ME, Carrión‐Vázquez M. Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations. Progress in Neurobiology. 2025. doi:10.1016/j.pneurobio.2025.102734. PMID: 40024279.
BibTeX
@article{lopezgarcia2025-40024279,
author = {López-García, Paula and Tejero-Ojeda, María M. and Vaquero, María Eugenia and Carrión‐Vázquez, Mariano},
title = {{Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations}},
journal = {Progress in Neurobiology},
year = {2025},
doi = {10.1016/j.pneurobio.2025.102734},
pmid = {40024279},
url = {https://doi.org/10.1016/j.pneurobio.2025.102734}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.